Up to 80% of patients with systemic lupus erythematosus (SLE) are treated with nonsteroidal anti-inflammatory drugs (NSAID) for musculoskeletal symptoms, serositis and headache. This survey reviews the literature on non-selective and selective inhibitors of cyclooxygenases, with an emphasis on the efficacy and safety profile reported in SLE patients. No lupus-specific data on gastro-intestinal side effects of NSAID exist. Both non-selective Cox inhibitors and selective Cox-2 inhibitors induce renal side effects, including sodium retention and reduction of the glomerular filtration rate. Lupus nephritis is a risk factor for NSAID-induced acute renal failure, but not for rare idiosyncratic toxic renal reactions to NSAID. In refractory nephrotic syndrome, NSAID have been used successfully. Cutaneous and allergic reactions to NSAID are increased in SLE patients as well as hepatotoxic effects, particularly with high dose aspirin. Whereas a variety of central nervous system side effects of NSAID are probably no more common in SLE patients than others, aseptic meningitis has been reported more frequently. Ovulation and pregnancy can be adversely affected by Cox inhibitors. The antiplatelet effect of aspirin and non-selective Cox inhibitors has a therapeutic potential in patients with antiphospholipid syndrome (APS). In summary, treatment of SLE with NSAID requires awareness for the increased frequency of some side effects and close monitoring of toxicity.
Wallace DJ , Metzger AL , Klinenberg JR . NSAID usage patterns by rheumatologists in the treatment of SLE . J Rheumatol1989; 16: 557–560 .
2.
Worrall JG , Snaith ML , Batchelor JR , Isenberg DA . SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up . Q JM1990; 74: 319–330 .
3.
Cervera R , Khamashta MA , Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5 y period. A multicenter, prospective study of 1,000 patients . Medicine1999; 78: 167–175 .
4.
Khamashta MA , Cuadrado MJ , Mujic F et al. The management of thrombosis in the antiphospholipid-antibody syndrome . New Engl J Med1995; 332: 993–997 .
5.
Dubois EL . Ibuprofen for systemic lupus erythematosus (letter) . New Engl J Med1975; 293: 779–779 .
6.
Gergely P . Long term use of piroxicam in the treatment of systemic lupus erythematosus . Ther Hung1989; 37: 83–85 .
7.
Ramsey-Goldman R , Mientus JM , Medsger TA . Toxicity of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with systemic lupus erythematosus (SLE) (abstract) . Arthritis Rheum1989; 32 (Suppl): S75–s75 .
8.
Spangler RS . Cyclooxygenase 1 and 2 in rheumatic disease: Implications for nonsteroidal anti-inflammatory drug therapy . Semin Arthritis Rheum1996; 26: 435–447 .
9.
Patrono C , Ciabattoni G , Remuzzi G et al. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus . J Clin Invest1985; 76: 1011–1018 .
10.
Ferro D , Basili S , Roccaforte S et al. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus . Arthritis Rheum1999; 42: 2689–2697 .
11.
Yoshida T , Ichikawa Y , Tojo T , Homma M . Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904 . Lupus1996; 5: 129–138 .
12.
Singh G , Rosen Ramey D , Morfeld D et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis . Arch Intern Med1996; 156: 1530–1536 .
13.
Sultan SM , Ioannou Y , Isenberg DA . A review of gastrointestinal manifestations of systemic lupus erythematosus . Rheumatology1999; 38: 917–932 .
14.
Emery P , Zeidler H , Kvien TK et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double blind comparison . Lancet1999; 354: 2106–2111 .
15.
Ehrich EW , Schnitzer TJ , Mcllwain H et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib . J Rheumatol1999; 26: 2438–2447 .
16.
Köhoff M , Gröne HJ , Klein T et al. Localisation of cyclooxygenase-1 and 2 in adult and fetal human kidney: implication for renal function . Am J Physiol1997; 272: F460–F468 .
17.
Burton DR . Clinical Physiology of Acid-Base and Electrolyte Disorders, 4th edn.McGraw-Hill: New York , 1994, pp 178–184.
18.
Cook ME , Wallin JD , Thakur VD et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function . J Rheumatol1997; 24: 1137–1144 .
19.
Catella-Lawson F , McAdam B , Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids . JPET1999; 289: 735–741 .
20.
Rossat J , Maillard M , Nussberger J et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects . Clin Pharmacol Ther1999; 66: 76–84 .
21.
Ter Borg EJ , de Jong PE , Meijer S , Kallenberg CGM . Renal effects of indomethacin in patients with systemic lupus erythematosus . Nephron1989; 53: 238–243 .
22.
Pierucci A , Simonetti BM , Pecci G et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis . New Engl J Med1989; 320: 421–425 .
23.
Yoshida T , Kameda H , Ichikawa Y et al. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephrits . J Rheumatol1996; 23: 1719–1724 .
Warren GV , Korbet SM , Schwartz MM , Lewis EJ . Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs . Am J Kidney Dis1989; 13: 127–130 .
26.
Espinoza LR , Jara LJ , Martinez-Osuna P et al. Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy . Lupus1993; 2: 9–14 .
27.
Hegg JE , de Jong PE , Vriesendorp R , de Zeeuw D . Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril . Am J Nephrol1990; 10: 94–97 .
28.
Bigby M , Stern R . Cutaneous reactions to nonsteroidal antiinflammatory drugs . J Am Acad Dermatol1985; 12: 866–876 .
29.
Wang CR , Chuang CY , Chen CY . Drug allergy in Chinese patients with systemic lupus erythematosus . J Rheumatol1993; 20: 399–400 .
30.
Stern RS . Phototoxic reactions to piroxicam and other nonsteroidal anti-inflammatory agents . New Engl J Med1983; 309: 186–187 .
31.
Stern RS , Bigby M . An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs . JAMA1984; 252: 1433–1437 .
32.
Pichler WJ , Schnyder B , Zanni MP et al. Role of T cells in drug allergies . Allergy1998; 53: 225–232 .
33.
Rainsford KD . Mechanisms of adverse reactions in the skin from antirheumatic drugs. In: Rainsford KD (ed). Side Effects of Anti Inflammatory Drugs IV. Kluwer: Dordrecht1997, pp 297–303.
34.
Roura M , Lopez-Gil F , Umbert P . Systemic lupus erythematosus exacerbated by piroxicam . Dermatologica1991; 182: 56–58 .
35.
Senécal JL , Chartier S , Rothfield N . Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-ro(SSA) and anti-la(SSB) antibodies and treatment with indomethacin and hydroxychloroquine . J Rheumatol1995; 22: 868–875 .
36.
Simon LS , Lanza FL , Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor . Arthritis Rheum1998; 41: 1591–1602 .
37.
Runyon BA , LaBrecque DR , Anuras S . The spectrum of liver disease in systemic lupus erythematosus . Am J Med1980; 69: 187–194 .
38.
Dhand AK , LaBrecque DR , Metzger J . Sulindac (Clinoril) hepatitis . Gastroenterology1981; 80: 585–586 .
39.
Park GD , Spector R , Headstream T , Goldberg M . Serious adverse reactions associated with sulindac . Arch Intern Med1982; 142: 1292–1294 .
40.
Seaman WE , Plotz PH . Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers . Arthritis Rheum1976; 19: 155–160 .
41.
Travers RL , Hughes GRV . Salicylate hepatotoxicity in systemic lupus erythematosus: a common occurrence?Br Med J1978; 2: 1532–1533 .
42.
Hannequin JR , Doffod M , Schmutz G . Hepatitis secondary to non steroid anti-inflammatory drugs . Rev Rhum Malad Ostéo Artic1988; 55: 983–988 .
43.
Breder CD . Cyclooxygenase systems in the mammalian brain . Ann N Y Acad Sci1997; 813: 296–301 .
44.
May FE , Moore MT , Stewart RB , Hale WE . Lack of association of nonsteroidal anti-inflammatory drug use and cognitive decline in the elderly . Gerontology1992; 38: 275–279 .
45.
Hoppmann RA , Peden JG , Ober SK . Central nervous system side effects of nonsteroidal anti-inflammatory drugs . Arch Intern Med1991; 151: 1309–1313 .
46.
Agus B , Nelson J , Kramer N et al. Acute central nervous system symptoms caused by ibuprofen in connective tissue disease . J Rheumatol1990; 17: 1094–1096 .
47.
Shoenfeld Y , Livni E , Shaklai M , Pinkhas J . Sensitization to ibuprofen in systemic lupus erythematosus . JAMA1980; 244: 547–548 .
48.
Berliner S , Weinberger A , Shoenfeld Y et al. Ibuprofen may induce meningitis in (NZB6NZW) F mice . Arthritis Rheum1985; 28: 104–107 .
49.
Akil M , Amos RS , Stewart P . Infertility may sometimes be associated with NSAID consumption . Br J Rheumatol1996; 35: 76–78 .
50.
Smith G , Roberts R , Hall C , Nuki G . Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs . Br J Rheumatol1996; 35: 458–462 .
51.
Dinchuk JE , Car BD , Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II . Nature1995; 378: 406–409 .
52.
éstensen M , Ramsey-Goldman R . Treatment of inflammatory rheumatic disorders in pregnancy. What are the safest treatment options?Drug Safety1998; 5: 389–410 .
53.
Clyman RI , Hardy P , Waleh N et al. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus . Am J Physiol1999; 276: R913–R921 .
54.
Amigo MC , Khamashta MA , Hughes GRV . Antiphospholipid syndrome in SLE . BaillieÁre's Clin Rheumatol1998; 12: 477–493 .
55.
Gupta S , McCune WJ , Kaplan MJ et al. Thrombosis and ischemia in patients with systemic lupus erythematosus treated with celecoxib: a series of two cases . Arthritis Rheum1999; 42 (Suppl): S149–S149 (abstract).
56.
Hermiller JB , Bambach D , Thompson MJ et al. Vasodilatators and prostaglandin inhibitors in primary pulmonary hypertension . Ann Intern Med1982; 97: 480–489 .
57.
Adnot S , Defouilloy C , Brun-Buisson C et al. Effects of indomethacin on pulmonary hemodynamics and gas exchange in patients with pulmonary artery hypertension, interference with hydralazine . Am Rev Respir Dis1987; 136: 1343–1349 .
58.
Tonkin AL , Wing LMH . Interactions of non-steroidal anti-inflammatory drugs . BallieÁre's Clin Rheumatol1988; 2: 455–483 .
59.
Karim A , Tolbert DS , Hunt TL et al. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis . J Rheumatol1999; 26: 2539–2543 .
60.
The Medical Research Council's General Practice Research Framework . Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk . Lancet1998; 351: 233–241 .
